Drugs / SYHA1813
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06157918 | Dec 2023 → Jan 2024 | — | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06682611 | Nov 2024 → Nov 2026 expected | — | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06739213 | Jan 2025 → Jan 2027 expected | meningioma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07613450 | May 2026 → Jul 2029 expected | meningioma | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHA1813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06157918 ↗ |
| Route | Oral | “SYHA1813 oral solution, 25mg, oral” NCT06157918 ↗ |